Delayed-release stimulant used to treat ADHD may be less subject to abuse
A team led by Massachusetts General Hospital (MGH) researchers has found that a delayed-release stimulant used to treat attention-deficit hyperactivity disorder (ADHD) may be less likely to be abused than other stimulant drugs. Study participants taking therapeutic oral doses of Concerta, a once-daily form of the drug methylphenidate, did not report perceiving and enjoying the drugs subjective effects, features that are associated with a medications potential for abuse. The report appears in the March 2006 issue of The American Journal of Psychiatry.
"We know that drugs that cause euphoria are potentially abusable, and euphoria requires rapid delivery to the brain. Using sophisticated PET scan imaging, we were able to examine the rate of delivery of both rapid- and delayed-release formulations of methylphenidate and correlate those results with how the drugs felt to study volunteers," says Thomas Spencer, MD, of the MGH Pediatric Psychopharmacology Unit, the papers lead author. "The ability to show that rate of brain delivery may determine abuse potential is important to our understanding of the safety of different formulations."
Methylphenidate and other stimulant drugs used to treat ADHD act by blocking the dopamine transporter, a molecule on brain cells that takes up the neurotransmitter dopamine, raising its level in the brain. Studies have shown that the brains of ADHD patients have abnormal regulation of dopamine, which plays a key role in the control of movement, behavior and attention. While stimulants are effective for controlling ADHD symptoms, the drugs are also subject to abuse, so the current study was designed to compare the abuse potential of two formulations of methylphenidate.
The researchers compared a traditional, quick-release form of the drug with Concerta, a formulation that is released over 12 hours to produce a gradual increase in blood levels. With Concerta, the drug passes slowly through a hole in capsules that do not dissolve, reducing the possibility that the gradual-release feature might be bypassed. Study participants received the two medications at dosages designed to produce comparable peak levels in the blood and brain.
Twelve adult volunteers, none diagnosed with ADHD or any neurological or psychiatric disorder, were randomly assigned to receive either the immediate-release or delayed-release form of methylphenidate on two separate days. PET scans – which showed whether or not the dopamine transporter molecule was occupied by the medication – were taken the day before drug administration as a baseline, one and three hours after the first drug administration and five and seven hours after a second drug administration on a different day. During the 10 hours after each drug administration, hourly blood samples were taken from the volunteers, who also completed hourly questionnaires regarding whether they were aware of the drugs effects and whether they enjoyed or disliked those effects.
As expected, the delayed-release formulation took longer to produce maximum blood levels and blockade of the dopamine transporter than did the immediate-release drug. While most of those receiving immediate-release methylphenidate reported detecting and enjoying the drugs activity, few of those receiving the delayed-release form were aware of or enjoyed the drugs effects.
"The differing reports on feeling and liking the drug effects occurred despite using larger doses of the delayed-release formulation and the equivalent peak blood and brain levels," says Spencer. "Previous studies have showed that both versions are effective for treating ADHD. Whether delayed- or sustained-release formulations of other potentially abusable ADHD drugs share the same safety characteristics needs be studied, since different forms vary in the levels and timing of drug delivery." Spencer is an associate professor of Psychiatry at Harvard Medical School.
Sue McGreevey | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...